Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 34,500 shares, a drop of 31.7% from the September 30th total of 50,500 shares. Currently, 2.5% of the shares of the company are short sold. Based on an average daily volume of 106,300 shares, the days-to-cover ratio is presently 0.3 days.

Insider Buying and Selling at Vaccinex

In other Vaccinex news, Director Albert Friedberg purchased 200,000 shares of Vaccinex stock in a transaction on Wednesday, July 31st. The stock was bought at an average price of $6.15 per share, for a total transaction of $1,230,000.00. Following the transaction, the director now owns 762,415 shares of the company’s stock, valued at $4,688,852.25. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders have bought 203,753 shares of company stock worth $1,247,255. 51.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vaccinex

An institutional investor recently raised its position in Vaccinex stock. AIGH Capital Management LLC boosted its holdings in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,958 shares of the company’s stock after purchasing an additional 50,593 shares during the period. AIGH Capital Management LLC owned approximately 6.90% of Vaccinex worth $707,000 at the end of the most recent quarter. 50.11% of the stock is owned by institutional investors and hedge funds.

Vaccinex Price Performance

Shares of Vaccinex stock traded up $0.16 on Tuesday, hitting $3.90. The company had a trading volume of 131,029 shares, compared to its average volume of 50,323. Vaccinex has a 52 week low of $1.39 and a 52 week high of $13.45. The company has a market cap of $6.74 million, a PE ratio of -0.07 and a beta of 0.96. The business has a 50-day simple moving average of $4.09 and a 200-day simple moving average of $5.33.

Vaccinex (NASDAQ:VCNX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($3.10) EPS for the quarter. The firm had revenue of $0.23 million during the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.